Overview
Angioosteohypertrophic syndrome (Orphanet code 2346) is an obsolete disease designation that historically referred to a condition now more commonly known as Klippel-Trénaunay syndrome (KTS). Klippel-Trénaunay syndrome is a rare congenital vascular disorder characterized by a classic triad of clinical features: capillary malformations (port-wine stains), venous malformations with or without lymphatic abnormalities, and soft tissue and/or bony hypertrophy (overgrowth) of an affected limb. The condition typically affects one lower extremity, though it can involve upper limbs or multiple limbs. The vascular malformations can range from superficial capillary stains to deep venous anomalies, and the limb overgrowth may be progressive during childhood. The condition primarily affects the vascular system, skeletal system, and soft tissues. Complications can include thrombophlebitis, deep vein thrombosis, pulmonary embolism, lymphedema, cellulitis, and bleeding from vascular malformations. Internal organ involvement, particularly of the gastrointestinal or genitourinary tract, may also occur. Pain and functional impairment of the affected limb are common concerns. Treatment is largely supportive and symptom-directed. Compression garments are commonly used to manage lymphedema and venous insufficiency. Sclerotherapy or laser therapy may be employed for symptomatic vascular malformations. Surgical interventions, including debulking procedures or epiphysiodesis to address limb length discrepancy, may be considered in selected cases. More recently, targeted therapies such as sirolimus (an mTOR inhibitor) have been explored for managing vascular anomalies. A multidisciplinary approach involving vascular specialists, orthopedic surgeons, and dermatologists is recommended. As this entry is marked obsolete, clinicians and patients should refer to the current Klippel-Trénaunay syndrome classification for up-to-date information.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Angioosteohypertrophic syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: Angioosteohypertrophic syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Angioosteohypertrophic syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Angioosteohypertrophic syndrome.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Angioosteohypertrophic syndrome.
Start the conversation →Latest news about OBSOLETE: Angioosteohypertrophic syndrome
No recent news articles for OBSOLETE: Angioosteohypertrophic syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about OBSOLETE: Angioosteohypertrophic syndrome
What is OBSOLETE: Angioosteohypertrophic syndrome?
Angioosteohypertrophic syndrome (Orphanet code 2346) is an obsolete disease designation that historically referred to a condition now more commonly known as Klippel-Trénaunay syndrome (KTS). Klippel-Trénaunay syndrome is a rare congenital vascular disorder characterized by a classic triad of clinical features: capillary malformations (port-wine stains), venous malformations with or without lymphatic abnormalities, and soft tissue and/or bony hypertrophy (overgrowth) of an affected limb. The condition typically affects one lower extremity, though it can involve upper limbs or multiple limbs. Th
How is OBSOLETE: Angioosteohypertrophic syndrome inherited?
OBSOLETE: Angioosteohypertrophic syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: Angioosteohypertrophic syndrome typically begin?
Typical onset of OBSOLETE: Angioosteohypertrophic syndrome is neonatal. Age of onset can vary across affected individuals.